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Novelty statements: 
 Our study participants had gestational diabetes treated with insulin thus representing 
women with more severe disease with higher risk for adverse materno-fetal outcomes. 
 
 We showed that the use of continuous glucose monitoring in women with GDM on 
insulin improved glycemic control with no significant increase in symptomatic 
hypoglycaemia. 
 
 CGM may have a role in improving glycaemic control in gestational diabetes on insulin, 
which in turn could result in better materno-fetal outcomes. 
 
 This could have important clinical implications in management, especially when 
gestational diabetes occurs at a higher rate in Asia 
 
 
ABSTRACT 
Background: Good glycaemic control in gestational diabetes mellitus (GDM) improves pregnancy 
outcomes and reduces perinatal morbidity. Continuous glucose monitoring (CGM) improves 
HbA1c and pregnancy outcomes in pre-gestational diabetes, however its role has not been 
established in GDM. 
Objective: To determine if therapeutic, retrospective CGM improves HbA1c with less 
hypoglycaemia in insulin treated women with GDM. 
Methods: This prospective, randomized-controlled, open-label trial enrolled 50 insulin-treated 
GDM mothers randomized to either retrospective-CGM (6-day-sensor) at 28, 32, and 36-weeks 
gestation (Group-1, CGM, n=25) or usual antenatal care without CGM (Group-2, control, n=25).  
All women performed 7-point capillary blood glucose (CBG) profiles at least 3-days per week and 
recorded hypoglycaemic events (symptomatic and asymptomatic CBG <3.5mmol/L; non-fasting 
<4.0mmol/L). HbA1c was measured at 28, 33 and 37-weeks. In Group-1, both CGM and CBG 
data were used to manage diabetes, while Group-2 mothers were managed based on CBG data 
alone.  
Results: Baseline characteristics (age, pre-pregnancy BMI, HbA1c, total insulin dose) were similar 
between groups. There was a lower increase in HbA1c from enrolment at week 28 until 37 weeks 
gestation in CGM mothers (∆HbA1c: CGM +1mmol/mol (0.09%), control +3mmol/mol (0.30%), 
p=0.024. Mean HbA1c remained unchanged throughout trial duration in the CGM group, but rose 
significantly in controls as pregnancy advanced. Mean HbA1c in the CGM group was lower at 37 
weeks compared with controls (33±4mmol/mol (5.2±0.4%) vs 38±7mmol/mol (5.6± 0.6 %), 
p<0.006.  92% of CGM mothers achieved an HbA1c ≤39mmol/mol (≤5.8%) at 37-weeks 
compared to 68% of controls (p=0.012). Neither group experienced severe hypoglycaemia.  
Conclusion: CGM use may be beneficial in insulin-treated GDM as it improves HbA1c compared 
with usual antenatal-care without increasing severe hypoglycaemia. 
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BACKGROUND  
Gestational diabetes mellitus (GDM) is defined as glucose-intolerance of variable severity with 
onset or first recognition during pregnancy and is associated with a higher frequency of adverse 
materno-fetal outcomes[1] . The incidence of GDM is increasing globally. Asian ethnicity is 
emerging as a recognized risk factor, with prevalence rates as high as 11.4% in Malaysia and 14% 
in South India [2,3]. Poor glycaemic-control in GDM has been demonstrated to increase perinatal 
mortality/morbidity rates[4].Treatment of GDM has been shown to reduce serious perinatal-
complications, and perinatal-outcomes are significantly improved with better glycaemic-
control[4,5]. In particular, intensive treatment of GDM reduces macrosomia. Crowther et al 
reported a reduction from 21% (no treatment) to 10% (treatment) [5] while Landon et al[4] 
demonstrated that achieving blood-glucose targets  of 5.3mmol/L(fasting) and 6.7mmol/L(2-hours 
postprandial) results in a macrosomia-rate of 5.9% compared with 14.3% in the control arm. 
CGM advantages include the ability to monitor nocturnal-glucose levels and detect post-prandial 
hyperglycaemic excursions which are the blind-spots of conventional capillary blood glucose 
(CBG) monitoring[6,7].Both real-time and closed CGM use in non-gravid women with Type 1 
Diabetes Mellitus (T1DM) has been shown to improve glycaemic-control and reduce 
hypoglycaemia [8,9,10,11] 
In pregnancies complicated by diabetes, where tight glucose-control is necessary to improve 
materno-fetal outcomes, CGM may have a role in fine-tuning management and achieving 
recommended targets recommended as it provides comprehensive 24-hour glucose-profiles 
encompassing post-prandial glucose excursions [12], as well as details of average time-spent-in- 
hypoglycaemia, euglycaemia and hyperglycaemia for periods of 3-6 days, in comparison with 4–
8 point capillary blood glucose (CBG) profiles[13]. A trial of retrospective CGM in women with 
pre-gestational diabetes by Murphy et al, demonstrated that those who received CGM during 
pregnancy had better glycaemic control with lower HbA1c and reduced macrosomia risk compared 
to women who received regular antenatal care [14]. The recently published CONCEPTT trial also 
demonstrated improved neonatal outcomes in women with type 1 diabetes who used real-time 
CGM [15]. The American Association of Clinical Endocrinologists (AACE) currently 
recommends CGM use in pregnant women with T1DM[16]. Several groups, in mainly 
observational studies, have demonstrated CGM’s diagnostic efficacy in detecting hyperglycaemia 
and hypoglycaemia missed by conventional CBG testing in women with GDM [6,7,12,17], while 
others have demonstrated CGM use leads to changes in clinical decision making[6,12,18]. Yu et 
al have shown that periodic 72-hour retrospective CGM use in  women with diet-controlled GDM 
(the majority  of whom were were still on diet alone by trial end) improves pregnancy outcomes 
when compared with a control group of mothers using CBG monitoring alone[19]. This 
interventional study however, did not report HbA1c outcomes.  
To our knowledge, there have been no published trials on the efficacy of retrospective CGM in 
exclusively insulin-treated women with GDM, specifically examining glycaemic outcomes such 
as HbA1c and hypoglycaemia during longitudinal follow-up until delivery. We therefore designed 
an open-label randomized controlled trial to evaluate prospectively evaluate the therapeutic effect 
of retrospective CGM use in insulin-treated women with GDM. We hypothesized professional 
CGM use at 4-week intervals in the second-half of pregnancy would improve glycaemic control 
and reduce hypoglycaemia.  
 
 
METHODOLOGY  
This prospective, open-label, randomized controlled trial enrolled 57 insulin-treated women with 
GDM (Figure1) receiving multi-disciplinary team care from consultant obstetricians, 
endocrinologists, dietitians and diabetes nurse educators between April 2013-April 2015 at a 
tertiary care antenatal-clinic in Kuala Lumpur, Malaysia. The study was approved by the local 
ethics committee (Medical Research Ethics Committee of University of Malaya Medical Centre) 
and the women provided informed, -written consent.   
The inclusion and exclusion criteria are stated in Table 1. Our centre practises opportunistic 
universal screening during the 1st encounter with the obstetrician with a 75g-OGTT using 
diagnostic criteria of a fasting plasma glucose ≥5.1 and/or a 2 hour post load plasma glucose of 
≥7.8mmol/L as per local guidelines. If an early screen is negative patients are re-screened at 24-
28 weeks gestation. 
The main exclusion criteria were pre-gestational T1DM/T2DM or newly diagnosed overt-diabetes 
in pregnancy (HbA1c ≥48mmol/mol (6.5%), fasting glucose ≥7.0mmol/L, random glucose 
≥11.1mmol/L).   
 
Study protocol 
All participants gave fully informed consent and were randomized in blocks of 4 using sealed 
envelopes into 2 groups (25 women per group) by a research assistant. The participants randomly 
chose one of 4 sealed envelopes with the treatment-allocation within, those who withdrew were 
replaced by eligible women who consented to participate and were then randomized in the same 
manner i.e. blocks of four. Six6 women randomized into the CGM group withdrew voluntarily 
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even before the start of the study and did not undergot have any CGM done. They were replaced 
by another 6 participants selected randomly. 1 participant withdrew within the first CGM, hence 
she was replaced by another participant also selected randomly. Reasons for withdrawal were 
religious beliefs, inability to commit to the scheduled appointments and inconvenience of wearing 
CGM. 
Baseline demographic, anthropometric and clinical information were obtained via interview using 
a structured-questionnaire. Every effort was made to provide equal-care and education to both 
groups. Group-1 underwent CGM at 28, 32 and 36-weeks gestation in addition to standard 
antenatal-care while Group-2 received only standard antenatal-care. CGM-group women were 
managed based on CGM and CBG data, while controls were managed based on CBG alone. 
Participants enrolled in both arms were required to measure CBG seven times per day (fasting,pre-
and 2hours post-prandial, pre-bed) at least 3 days per week. In addition, in order to calibrate the 
CGM-device, those in Group-1 had to monitor CBG a minimum of 4 times per day during the 6 
days of sensor-use. All participants were taught by trained diabetes-nurse-educators to self-
monitor blood-glucose and those receiving CGM were given additional training on how to use the 
CGM.  All participants in both groups were taught to record meals, CBG values, hypoglycaemic 
events, insulin timing and dosage, and exercise in standardized log-sheets.   As per standard in our 
centre, women with GDM are reviewed weekly if glucose levels are off-target and 2-weekly if 
within target until 36-weeks-gestation. After 36-weeks, all women are reviewed weekly until 
delivery.     
Similar glycaemic targets for GDM (standard of care in our centre) were used in both groups: 
fasting 3.5 – 5.0mmol/L, pre-meals 4.0 – 5.8mmol/L, 2-hours post-prandial 4.0 - 6.7mmol/Ll. 
However in the CGM group, an additional target of 1-hour postprandial <.7.8 mmol/Ll  on CGM 
was also used. In all participants, CBG, food-diaries and hypoglycaemia-logs were collected and 
reviewed at each visit. They were asked at every visit about any hypoglycaemic events that were 
not logged and these were also documented by the researchers. Adjustments were made to therapy 
if participants did not achieve target glucose despite best efforts at diet-modification. Participants 
with fasting-glucose<3.5mmol/L and non-fasting glucose<4mmol/L or symptoms of 
hypoglycaemia (regardless of glucose-level) while on insulin had their insulin-doses reduced 
accordingly as per standard practice. 
The CGM device used was the Medtronic iPro2 Enlite 6-day sensor which measures interstitial 
fluid glucose within a range of 2.2-22mmol/L. The sensor was inserted over the abdomen on Day-
1 and removed Day-7.  During this period CGM glucose measurements were not accessible to the 
women or management-team.  
In the group that underwent CGM, after sensor removal (Day-7) at weeks 29, 33 and 37, stored 
CGM-data were downloaded using the manufacturer’s software (Carelink iPro-Therapy 
Management Software) and printed reports were given to both participant and doctor the same 
day. The CGM-data were reviewed by the endocrinologist on the day of removal, and findings 
discussed with participants, taking note of abnormal glycemic -patterns. They were advised to 
identify any possible reasons for these patterns, and their diet, exercise as well as insulin-dose were 
taken into consideration. The CGM-data together with CBG results were used to make therapeutic 
decisions.  
While for the purpose of data-analysis, euglycaemia on CGM was defined as glucose at any time-
point within the range 3.5–6.7mmol/L, however therapeutic decision-making was modified based 
upon an upper limit postprandial target of 7.8mmol/L at 1hour and not 6.7mmol/L.  
HbA1c was measured in all women at week-28, 33 and 37. The HbA1c assays were DCCT-aligned 
and IFCC/NGSP-certified. Other parameters such as weight and urine ketones were monitored at 
every visit. All women had fetal ultrasound-scans at regular intervals as decided by the 
obstetrician. Fetal parameters were monitored and plotted on customized local fetal growth charts. 
Birth-information (mode-of-delivery, maternal complications) as well as neonatal-outcome 
parameters such as birth-weight, gestational-age at delivery, APGAR score, hypoglycaemia, 
jaundice and neonatal ICU admission were retrieved from hospital files. 
The prespecified primary outcome was change in HbA1c from 28-37 weeks. The secondary 
outcome was maternal hypoglycaemia. 
Power Calculations 
Based upon Murphy’s research in women with pre-gestational diabetes[14],a minimum sample 
size of 36 was required to achieve an 80% power to detect a 0.6 % reduction in HbA1c at P=0.05.  
To allow for attrition, a sample size of 50(25 per group) was decided upon. 
Statistical analysis:  
SPSS (Statistical Package for the Social Services) IBM version 20.0 software was used for data-
analysis. Data are presented as means (±Standard Deviation) (continuous parametric-variables), 
medians (Q25–Q75)(continuous non-parametric variables) and percentages(categorical-data). 
Differences between groups were evaluated using t-test and chi-squared-test. Within group 
differences were evaluated with paired t-testing. Relationships between continuous variables were 
analyzed using Pearson’s correlation-test. Statistical significance threshold was p< 0.05.  
 
RESULTS:  
Baseline characteristics 
A total of 50 women completed the protocol (Figure 1) with 25 randomized to the CGM-arm 
(Group -1) and 25 to the cControl-arm (Group -2).   
 Baseline characteristics were not different between groups except for an earlier gestational age at 
diagnosis of GDM in the CGM -arm (Table 2).  Although 60 % (15/25) of women in the CGM -
arm and 36 % (9/25)  in the control-arm had GDM diagnosed before 20 weeks gestation, all women 
were asymptomatic, had no pre-gravid diagnosis of hyperglycaemia and had a baseline HbA1c  < 
48mmol/mol (6.5%). 
Therapy prior to study -enrolment 
Duration of metformin therapy and insulin therapy prior to enrolment were not significantly 
different between groups. Intensification of insulin therapy (change in total daily dose and number 
of injections) was not different between groups. The frequency of health-care provider contact 
(dietitian, diabetologist, diabetes educator nurse) was not different between groups prior to study 
enrolment.(Table 2) 
Glycaemic outcomes 
Both groups had a similar baseline HbA1c 32±3mmol/mol (5.1±0.3%) vs. 34±6mmol/mol 
(5.3±0.5%), p=0.124 (Figure 2 and Table 3). As pregnancy advanced, the CGM-group had 
significantly lower HbA1c levels compared to standard-care at both 33 and 37-weeks (Figure 2 
and Table 3). Mean HbA1c remained unchanged throughout trial duration in the CGM-group, but 
steadily rose in the standard-care-group as pregnancy advanced.  Mean change in HbA1c from 
baseline (delta HbA1c) was only +1mmol/mol (0.09%) in the intervention-group compared to + 
3mmol/mol (0.30%) in standard care (p=0.024). A significantly higher proportion of women with 
CGM attained HbA1c<40mmol/mol (5.8%) at 37 weeks, compared to standard-care (92 v 68%; 
p= 0.012). There were no differences in fasting blood glucose and CBG values between groups at 
any of the time-points (Table-3). 
Hypoglycaemia  
Throughout the study-period, the majority of women in both groups experienced hypoglycaemia 
(symptomatic and asymptomatic) at least once after study enrollment, with a numerically greater 
frequency in the CGM-group which was not significant (92% vs. 72%, p=0.138). Overall 
hypoglycaemia frequency rates (combined symptomatic and asymptomatic) were significantly 
higher in the CGM group (Table 4). However there were no significant differences in symptomatic 
hypoglycaemia per person between groups. There were no episodes of severe hypoglycaemia in 
either group. Similar findings were seen during the last 4 week period, where there was more 
hypoglycaemia overall (both symptomatic and asymptomatic biochemical hypoglycaemia) in the 
CGM-group, but no difference in symptomatic hypoglycaemia alone between groups (Table 4). 
The majority of these episodes of hypoglycaemia (94.8%) were in the range 3-4mmol/L, 49.5 % 
of which were asymptomatic. 
Insulin therapy  
Total-insulin-requirement increased throughout pregnancy in both groups, however the quantum 
of increase from baseline to study-end did not differ significantly between groups (CGM vs 
control: 16.2±6.4 vs.11.8±13.6units, p=0.314. Total insulin -dose was also similar in both groups 
at baseline, 32 and 37 weeks. Numerically more women in the CGM-arm were on intensive 
insulin-therapy (>4 injections/day) at study-end (CGM 74% vs. standard-care 56%, p=0.195).  
Intensification of insulin therapy was similar in both groups. At pregnancy end, 72% of the CGM 
mothers were on insulin analogues compared to 52% in the standard care (p=0.057). Both groups 
had equal numbers of women on metformin (76% in each group) (Table 5) 
Frequency of Health-care Provider contact post-enrolment 
Post-enrolment, the CGM-group had more visits per person with the physician compared to 
standard care (8.6±1.5 vs 7.1±1.6 visits per person, p=0.001). Frequency of contact with the 
diabetologist, dietitian and diabetes educator nurse were not significantly different between 
groups. (Table 5) 
Maternal and fetal outcomes  
All women delivered by 38 weeks with the exception of 3 pre-term deliveries from the CGM-
group (at 32, 35 and 36 weeks respectively) and one from the control group at 36 weeks. Birth-
weight was non-significantly higher in the standard-care group compared with intervention (Table 
6). 
Continuous Glucose Monitoring 
All women in the intervention-arm underwent CGM as scheduled at 3 time-points except for two 
who had preterm-deliveries at 32-weeks(completed first CGM only) and 35-weeks( completed 
first and second CGM) respectively. The third patient who had a pre-term delivery at 36 weeks 
was able to complete her third CGM. As pregnancy advanced, percentage time-in-euglycaemia 
increased with concurrent reduction in time-in-hyperglycaemia, and there was no significant 
change in time-spent-in-hypoglycaemia from 1st to 3rd CGM (Table 7).  A mean of 21.4 hours/week 
of hyperglycaemia (glucose>6.7 mmol/L) was detected by the 1st CGM but missed by CBG. 
 DISCUSSION  
We have demonstrated that additional use of continuous glucose monitoring in insulin-treated 
women with gestational diabetes improves glycaemic control as evaluated by delta HbA1c , when 
compared with standard antenatal-care with self-monitoring of CBG alone. Delta HbA1c from 
enrolment at 28 weeks gestation to trial end was significantly lower in the intervention-group 
compared to standard-care (p=0.024).Over the course of pregnancy, CGM use was associated with 
a reduced time in hyperglycaemia without increasing time in hypoglycaemia, suggesting that the 
improvement in glycaemic control as measured by HbA1c was real.  At delivery, more GDM 
mothers who used CGM achieved an HbA1c <40mmol/mol (5.8%) compared to standard-care 
(92% vs. 68%, p<0.05). This improvement in HbA1c was most likely secondary to a greater 
awareness of hyperglycaemia in the CGM-arm, leading to greater intensification of insulin therapy 
by the endocrinologist, and perhaps more intensive diabetes self-management by the women. The 
CGM sensor detects hyperglycaemia over the entire postprandial-period,in contrast to CBG which 
evaluates discrete post-meal time-points, thus often missing peak prandial hyperglycaemia. In our 
study, a mean of 21.4 hours/week of hyperglycaemia (glucose>6.7 mmol/L) was detected by the 
1st CGM but missed by CBG. Although mean total-insulin-dose was similar in both groups at 
delivery, 85.7% CGM mothers versus 40% standard care mothers had treatment intensification 
(increased number of insulin injections per day from baseline, p=NS), with more CGM women on 
basal-bolus therapy compared with standard care (p=NS).  
There have been a few other randomized-controlled parallel-arm trials evaluating therapeutic, 
retrospective CGM-use in pregnancy [14,19,20]. To our knowledge, ours is the first to focus 
exclusively on insulin-treated women with GDM  using the 6-day sensor. Our trial is also the first 
to report details of concomitant insulin-therapy adjustments with CGM-use and focus on HbA1c 
outcomes in GDM.  Murphy et al, studied higher-risk mothers with pre-gestational diabetes, 
finding reductions in HbA1c with CGM use which began to emerge at 28-32 weeks with a final 
difference of 6 mmol/mol (0.6%) resulting in reduced macrosomia rates in the CGM 
arm[14].These women began CGM use  earlier in pregnancy  as they had established diabetes, 
thus undergoing more periods of monitoring (mean: 4.2 times over 24 weeks). Our women 
however, utilized CGM 3 times over 9 weeks (from 28-weeks gestation), yet demonstrated a 
significant 4 mmol/mol (0.4%) lowering of HbA1c in the intervention-arm. In contrast, Secher et 
al evaluated the use of periodic real time CGM in pre-gestational diabetes (Type 1 and 2) finding 
no differences in pregnancy outcomes, hypoglycaemia and HbA1c compared with standard-care 
[20]. These women had good glycaemic control similar to the standard care group, thus CGM 
might not have been able to effect much change. The recently published CONCEPTT trial [15] 
studied real-time CGM use in 215 type 1 diabetic women recruited before 13 weeks gestation. 
They found a modest redsuction in HbA1c of 2 mmol/mol (0.19%0 in the CGMcgm group at 34 
weeks, with less time spent in hyperglycaemia, similar to our findings in GDM. Moreover, they 
were able to demonstrate improvements in the neonatal outcomes of LGA, hypoglycaemia and 
ICU stay. Yu et al evaluated therapeutic, retrospective CGM in  336 women with GDM  (~20% of 
whom required insulin by trial -end)[19] This Chinese trial compared glycaemia  in both arms with 
72-hr CGM assessment at 2 time-points, at the first and 5th week of the trial, but only used sensor-
data in the intervention-arm to make management decisions. The trial compared supplementary 
therapeutic, retrospective 72-hour CGM use at 2-4 week regular intervals with CBG 7 times daily 
alone (from recruitment at ~26-weeks gestation until delivery) and found significantly lower 
glycaemic variability, shorter periods of hyperglycaemia and hypoglycaemia (<3.3 mmol/l) in the 
intervention arm after 5 weeks of CGM use. These differences in glycaemia as evaluated by CGM 
parameters were associated with lower infant birth-weight, macrosomia and LGA rate and a 
composite neonatal outcome rate in the CGM-intervention-arm.[19]. However, the effect of CGM 
on change in HbA1c by end-of-pregnancy was not reported..   
The role of HbA1c in monitoring glycaemia in GDM is not well-established. Current NICE 
guidelines recommend its’ use to assess risk, only in mothers with pre-gestational diabetes [21]. 
The reliability of HbA1c in pregnancy has been questioned due to confounding factors such as 
dilutional -anemia and shortened erythrocyte -lifespan [22]. However a strong association was 
found between HbA1c and average glucose values in pregnancy, thus validating its use to represent 
average glucose values in pregnancy [23]. Recent post hoc analysis of two trials of CGM in pre-
gestational diabetes has validated HbA1c as a measure of average glycaemia, albeit with a smaller 
estimated average blood glucose of 0.67 mmol/L per 11 mmol/mol (1.0%), compared to 1.0 – 2.0 
mmol/L per 11 mmol/mol (1.0%) in stable non pregnant people with type 1 and 2 diabetes [23]. 
Several key papers have linked higher HbA1c in GDM, in both 2nd and 3rd trimester with greater 
likelihood of macrosomia and adverse perinatal outcomes.   Lowe et al found that HbA1c at 24-
32 weeks gestation in GDM (after adjustments for age, BMI etc.) was independently predictive of 
macrosomia, with an odds-ratio of 1.93 in women with an HbA1c >40mmol/mol (5.8%), when 
compared with an HbA1c <26mmol/mol (4.5%) [24]. Another study showed that women with 
GDM with HbA1c >34mmol/mol (5.3%), either at diagnosis or pre-delivery, experienced more 
pregnancy-related adverse events [25]. Despite our small sample population that was powered to 
demonstrate significant differences in glycemic outcomes but not materno-fetal outcomes,  birth-
weight and LSCS-rates were non-significantly lower in the CGM-intervention-group.   
Extrapolating from the HAPO (Hyperglycaemia and Adverse Pregnancy Outcomes) study results, 
we can postulate that the lower mean HbA1c of <33mmol/mol (5.2%) in our CGM women, could 
have resulted in lower macrosomia rates and perinatal complication rates with a larger sample size 
[24,25]. Both our study arms achieved CBG similar to the landmark GDM trial by Landon et al 
[4].  HbA1c however is a better integrated measure of glycaemia than CBG profiles or the periodic 
CGM utilized by Yu et al. Although HbA1c reflects average glycaemia over 8-12 weeks, and 
therefore the outcome measure we used may have included the glycaemic period before enrolment 
at 28 weeks, it is well established that the last 30 days of glycaemia has the greatest impact on 
glycation [26]  Therefore, the  progressively increasing HbA1c in late pregnancy as  seen in our 
standard care women, may imply deteriorating glycaemic control in late-pregnancy asnd has been 
seen in other studies [14,15,20]. In addition, as our primary outcome was change in HbA1c from 
28-37 weeks, this reduces the possibility that the significant difference in delta A1c between the 
groups could be substantially affected by pharmacotherapy or lifestyle modification prior to 
enrolment at 28 weeks, despite the fact that a  proportion of patients had GDM diagnosed before 
20 weeks gestation. Additionally, baseline HbA1c at enrolment (28 weeks gestation) was not 
significantly different between the two arms thus making it likely that any change in HbA1c 
subsequently was secondary to the CGM intervention.  
There is little consensus on how to define ‘hypoglycaemia’ in pregnancy, with few studies 
reporting hypoglycaemia rates in insulin-treated women with GDM. The biochemical 
hypoglycaemia threshold of 4.0mmol/L in our trial was chosen as it is similar to that used in 
management of non-gravid women with type 1 and 2 diabetes on pharmacological treatment [27]. 
While NICE 2015 guidelines recommend keeping blood glucose above 4.0mmol/L in insulin-
treated diabetes in pregnancy [21], there is no guidance from the American -Diabetes -Association 
(ADA) on lower limits of desirable blood-glucose in GDM [28]..  
We found a higher incidence of hypoglycaemia in CGM-mothers compared with standard -care, 
especially in the last 4 weeks of the trial. 94.8% of hypoglycaemia episodes with concomitant CBG 
had readings in the range of 3-4mmol/L. However as interstitial -glucose levels are known to drop 
as low as 2.8mmol/L in healthy pregnancies[29,30]  and previous studies have used  cut-offs as 
low as 2.7mmol/L to diagnose hypoglycaemia in pregnancy[7,31], it is difficult to ascertain if these 
mainly asymptomatic reduced glucose readings are of clinical significance. In contrast, 
symptomatic hypoglycaemia, which may have more clinical relevance in pregnancy, was similar 
between groups. None of the participants had severe hypoglycaemia.  Importantly, CGM 
parameters available only in the intervention group demonstrate improvement in glycaemia with 
no increased time in hypoglycaemia indicating that women were not more hypoglycaemic as a 
result of better glycaemic control. The improvement in time in euglycaemia  can be explained by 
reduction in time in hyperglycaemia. Of note, there were no SGA babies in either arm and 
gestational weight gain in both groups were similar and as per IOM recommendations [32], 
indicating that improved glycaemic control in the intervention arm was not at the expense of 
reduced caloric intake.  We used CBG to enable valid comparisons of hypoglycaemia outcomes 
between groups as this was utilized by both.   This is a limitation of our study design, as it is 
possible standard care might have had episodes of low glucose missed by CBG.  Yu et al, on the 
other hand, used CGM in both groups, finding that time spent in hypoglycaemia was >5-fold higher 
in standard care compared to the intervention arm [19]. However, CGM is less reliable when it 
comes to the lower range of glucose values [33].  
  
To our knowledge, this is the first prospective, randomized controlled trial of therapeutic CGM 
use exclusively in insulin treated GDM, focusing on HbA1c and hypoglycaemia. Efforts were 
made to ensure both treatment-arms received equal care in terms of follow-up, dietary and diabetes 
nurse-educator advice, and optimization of insulin based on the glycaemic profiles available. We 
were limited both by a small sample-size, and, as a single-centre study where both 
participant/clinical practitioner were unnot blinded perhaps introducing bias. Many of our women 
were diagnosed with GDM at an earlyier gestation (<24 weeks), having been screened early, as 
our centre practices opportunistic universal screening during the 1st encounter with the obstetrician. 
Although none had a prior history of diabetes, this might indicate a proportion had undiagnosed 
pre-gestational glucose -intolerance first presenting in pregnancy. Diagnosis of GDM was 
significantly earlier in the CGM -group and consequently there was a longer duration of medical-
nutrition/pharmacological therapy in the intervention arm, hence raising the possibility that these 
differences might have contributed to improved glycaemic control in the CGM arm. While we did 
not collect data on actual frequency of CBG monitoring, it is theoretically possible that the CGM 
arm had potentially more CBG as they were required to monitor levels at least 4 times a day during 
each of the three six-day CGM periods. The CGM mothers also had slightly more frequent 
physician contact (mandatory on insertion/removal of CGM sensors). These factors could also 
have contributed to improved glycaemic outcomes in the intervention arm.  Our findings may not 
be generalizable to a setting where clinical guidelines mandate more frequent CBG such as 7 
points/day as recommended by NICE [21].  
In conclusion, we found that therapeutic CGM use just 3 times in the 3rd trimester in insulin-treated 
GDM and its associated intensive care, safely and effectively lowers HbA1c to a greater extent 
than standard antenatal care with CBG monitoring alone, without any increase in severe 
hypoglycaemia, Our findings suggest that CGM is a useful and safe tool in the management of 
insulin-treated women with GDM.   
 
 
FIGURE 1: Subject distribution and progression through trial 
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Inclusion Criteria: 
 Gestation less than 28-weeks   
 Singleton pregnancy 
 Confirmed GDM(75g oral glucose tolerance test: fasting plasma glucose >5.1mmol/L 
and/or 2-hour glucose > 7.8mmol/L)(based on local guidelines)1 
 GDM on insulin-therapy. 
 
Exclusion Criteria: 
 Pre-gestational T1DM/T2DM  
 Newly diagnosed overt-diabetes in pregnancy.[(HbA1c>48mmol/mol(6.5%), fasting 
glucose > 7.0mmol/l, random glucose > 11.1mmol/l) 
 Pregnancies with established fetal-anomalies or possible preterm-delivery secondary to 
maternal-disease besides GDM.  
 Known endogenous/exogenous Cushing’s-syndrome 
 Known chronic infections 
 
___________________________________________________________________________ 
 
Definitions 
 Maternal Hypoglycaemia: symptoms or asymptomatic biochemical 
hypoglycaemia(finger-stick-fasting glucose < 3.5mmol/L and non-fasting glucose < 
4.0mmol/L) 
 Euglycaemia on CGM: glucose levels 3.5 – 6.7mmol/l 
 Large for gestational age: birth weight >90th centile for gestation using Fenton 2013 
growth charts2 
 Small for gestational age: birth weight  below the 10th centile using Fenton 2013 growth 
charts2 
 Macrosomia: birth weight > 4 kg.  
 Birth weight ratio(BW adjusted for gestation and gender calculated with the Fenton 
2013 web-calculator(http://peditools.org/fenton2013) 
 Neonatal hypoglycemia  
 <4 hrs of life : <1.4 mmol/L 30 min after 1st feed;  <2.2 mmol/L 1hr after subsequent 
feeds3 
 4-24 hrs of life :  <1.9 mmol/L prefeed,  <2.5 mmol/L 1 hr after feed3 
1Opportunistic universal screening with 75 g OGTT in the fasting state. If an early screen is 
negative patients are re-screened at 24-28 weeks gestation. 
2www.ucalgary.ca/fenton  
3Adamkin DH et al. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 
2011;127(3);575-579. 
 
TABLE 1: Inclusion Criteria, Exclusion Criteria and Definitions 
 
 
 
 
  
      
    CGMS, n=25 
        
     Control, n=25 
 
 p-value 
Age, years a            32.8±4.5            32.6±4.9     0.882          
Race b 
   Malay             14 (56.0)             14 (56.0)     0.577            
   Chinese               5 (20.0)               2 (8.0) 
   Indian               5 (20.0)               8 (32.0) 
   Others               1  (4.0)               1 (4.0) 
Parityb    
   Primiparous   13 (52.0)         7 (28.0)                     0.083 
   Multiparous   12 (48.0)       18 (72.0)  
Family history of DMb             18 (72.0)       20 (80.0)   0.508 
BMI ,kg/m2 a                        
   Pre-gravid   28.3±4.8         27.3±5.6      0.481               
   28 weeks   31.4±5.3         30.3±5.4            0.475                      
Gestational age at diagnosis,weeksa   18.8±3.7         20.7±2.7            0.041 
HbA1c (28 weeks),mmol/mol(%)a   32±3(5.1±0.3)    34±6(5.3±0.5)      0.124               
Fasting blood glucose mmol/L 
(28 weeks)a 
    4.4±0.7 
 
     4.3±0.5      0.646 
 
Metformin therapy, from initiation to 
enrolment(28 weeks): 
   No. of women on metformin b 
   Duration of metformin ,weeks a 
 
Insulin therapy, from initiation to 
enrolment(28 weeks) : 
    Duration of insulin therapy,weeks a 
    Total insulin dose on initiation,units a 
    Gestation of insulin initiation,weeks a 
 
Intensification of insulin from initiation 
to enrolment (28 weeks) : 
    Change in total daily dose,units a 
    No. of women with increased no. of    
    injections, b 
 
    
    8 (32) 
    4.6±3.6 
  
 
  
    5.0±3.1  
  14.0±8.2 
  23.0±2.9  
 
 
 
3.2±8.8 
  
  2 (8) 
 
      
    11 (44) 
     4.8±3.4 
    
 
 
      4.9±3.0 
     14.0±8.2 
     23.0±2.9  
 
      
 
4.8±8.0 
 
 3 (12) 
 
     
 0.382 
 0.901 
  
 
 
0.926 
0.923 
0.320 
 
 
 
0.482 
 
0.193 
Insulin dose at enrolment 
(28weeks),unitsa 
     Total 
     Basal  
     Bolus 
 
 
28.0±16.0 
 8.3 ±6.5       
19.6±13.1 
 
 
28.3±15.9 
10.0±5.3       
18.4±12.6 
 
 
0.937               
0.323        
0.734                          
Frequency of Health-care provider 
contact before enrolment(28 weeks) c : 
       Physician/diabetologist 
       Diabetes nurse educator 
       Dietician  
 
 
2(1.5-4),[0-9] 
0,[0-2] 
2(1-2),[1-4] 
 
 
3(1.5-3.5),[0-8] 
0,[0-1] 
2(1-3),[1-6] 
 
 
0.992 
0.540 
0.226 
a Data expressed as mean±SD          b Data expressed as n (%)             c Data expressed as median no. of visits 
TABLE 2: Baseline characteristics of women with insulin-treated GDM in CGM and control group 
 FIGURE 2: Mean HbA1c at 28,33 and 37 weeks in CGM and standard care group 
 
 
 
 
 
 
 
 
 
 
 
32(5.1) 32(5.1)
33(5.2)
34(5.3)
36(5.4)
38(5.6)
4.8
4.9
5
5.1
5.2
5.3
5.4
5.5
5.6
5.7
28 weeks 33 weeks 37 weeks
CGMS
Standard care
*
⸹
⸹
Mean HbA1c 
mmol/mol(%)
*         compared to week 28, P=0.016
⸹ compared to week 28, P<0.001
⸹ compared to week 32 ,P=0.001
p=0.015
p=0.006
39 (5.7) 
 
 
 
38 (5.6) 
 
 
 
37 (5.5) 
 
 
 
36 (5.4) 
 
 
 
33 (5.2) 
 
 
 
32 (5.1) 
 
 
 
34 (5.3) 
 
 
 
31 (5.0) 
 
 
 
30 (4.9) 
 
 
 
29 (4.8) 
 
 
 
 a Data as expressed as means ± SD       
b CBG readings were obtained from a one week record at 3 time-points(week 28, 32 and 36)and an average value of 
the weekly readings were used for analysis. Pre-meal readings included pre-lunch, pre-dinner and pre-bed CBG. 2-
hours post-meal readings included 2-hour post breakfast, lunch and dinner CBG. 
TABLE 3: HbA1c, fFasting blood glucosesugar and capillary blood glucoseFingerstick-glucose in 
CGM and standard-care groups 
 
 
 CGMS CONTROL P VALUE 
HbA1c, mmol/mol(%) 
Week 28 
Week 33 
Week 37 
 
32±3(5.1±0.3) 
32±4(5.1±0.4) 
33±4(5.2±0.4) 
 
34±6(5.3±0.5)  
36±7(5.4±0.6)  
38±7(5.6±0.6) 
 
0.124 
0.015 
0.006 
Fasting Plasma Glucose at 37 weeks, mmol/La 4.1±0.7 4.6±0.9 0.101 
CSMBG, mmol/La,b 
 Week 28                                              Fasting 
                                                         Pre-meals 
                                          2-hours Post-meals 
 Week 32                                             Fasting 
                                                         Pre-meals 
                                          2-hours Post-meals 
  Week 36                                            Fasting 
                                                         Pre-meals 
                                          2-hours Post-meals 
 
 
4.9±0.4 
5.3±0.4 
6.0±0.5 
4.8±0.4 
5.2±0.4 
6.0±0.5 
4.6±0.4 
5.2±0.5 
5.9±0.5 
 
4.8±0.4  
5.2±0.4 
5.9±0.4 
4.7±0.4 
5.0±0.5 
5.8±0.4 
4.7±0.4 
5.1±0.4 
5.8±0.4 
 
0.299 
0.249 
0.688 
0.237 
0.064 
0.191 
0.400 
0.615 
0.500 
 HYPOGLYCAEMIA CGM  CONTROL P Value 
*Symptomatic, and 
asymptomatic [finger-stick 
glucose, fasting<3.5,nonfasting 
<4.0mmol/L] 
 
   
     Whole Study duration a 
       (28 -37 weeks) 
8.0 (3-14), [1, 34] 4.0 (1-6.5), [1, 12] 0.024    
     Last 4 weeksb 
       (34-37 weeks ) 
 
4.0 (3-9), [1, 16] 2.0 (1-3.25), [1, 4] 0.008 
Symptomatic  
( With or without capillary 
blood glucosefinger-stick 
glucose) 
 
   
      Whole Study durationa 
         (28-37 weeks) 
3.0 (1-6), [0,29] 1.0 (1-4), [0,10] 0.192 
      Last 4 weeks (34-37 weeks )b 
 
 
3.0 (0-4.5), [0,11] 1.0 (0-2), [0, 2] 0.091 
aData expressed as median no. of events per women for whole study duration 
bData expressed as median no. of events per women for 4 weeks 
 
TABLE 4: Hypoglycaemia rates in CGM and standard -care groups 
 
  CGM CONTROL P VALUE 
Total insulin dose, units a 
      28 weeks 
      33 weeks 
      37 weeks 
 
28.0±16.0 
38.8±21.4 
44.1±25.5 
 
28.3±15.9 
35.1±20.2 
40.1±23.2 
 
0.937 
0.539 
0.568 
Intensification of insulin from 
enrolment (28 weeks) till 37weeks: 
    Change in total daily dose, units a 
    No. of women with increased no.     
    of   injections, b             
 
 
16.1±16.4 
 
 6 (26) 
 
 
11.8±13.6 
 
5 (22) 
 
 
0.314 
No. of women on  
intensive insulin therapy at 37 weeks  
(> 4 injections/day)b 
 
 
17 (74) 
 
 
14 (56) 
 
 
0.195 
No. of women on  
insulin analogues at 37 weeks b 
(aspart, lispro, levemir) 
 
18 (72) 
 
 
13 (52) 
 
0.057 
 
No of women on metformin from 28 
weeks till 37 weeks b 
19 (76) 19 (76) 1.000 
Frequency of Health-care provider 
contact from enrolment(28 weeks) till 
37 weeks  c : 
       Physician/diabetologist 
       Diabetes nurse educator 
       Dietician  
 
 
 
7(5-8)[3-12] 
0[0-1] 
0(0-1)[0-2] 
 
 
 
6(5-8)[0-10] 
0[0-1] 
0(0-1)[0-9] 
 
 
 
0.617 
0.317 
0.956 
a Data expressed as mean±SD       b Data expressed as n (%)         c Data expressed as median no. of visits 
 
TABLE 5: Insulin, metformin therapy and health-care provider contact post-enrolment in CGM 
and standard-care group 
Maternal/Fetal Outcomes CGM, n=25 CONTROL, n=25 P Value 
Maternal Weight gain,kg a    
     Total   10.1±7.0        10.3±5.0 0.917               
     From 28 weeks        3.2±2.8        3.0±1.6 0.737               
Mean gestation at delivery, weeka   37.3±1.3    37.7±0.6 0.222             
Mode of Deliveryb    
    Vaginal  15 (60.0)    11 (44.0) 0.258 
     LSCS  10 (40.0)    14 (56.0)  
     Emergency   5  (50.0)      9 (64.3) 0.678 
             Elective   5  (50.0)     5 (35.7)  
Neonatal Mortalityb 0 0 NA 
Neonatal Morbidity    
   Preterm Delivery <37 weeksb 3(12.0)  1 (4.0)  0.609 
   Fetal anomalyb 0 0 NA 
   Neonatal hypoglycaemiab 1 (4.0)  2 (8.0) 1.000 
   NICU admissionb 1 (4.0)  1 (4.0) 1.000 
   Neonatal jaundiceb 5 (20.0)  4 (16.0) 1.000 
   Mean Birth weight(grams)a 2842.4±448.6 2976.0±473.5 0.311 
   Birth weight ratioa,c 
   Median birth weight centilea 
0.9±0.1  
20.6±21.9                                    
1.0±0.1 
28±27.3 
0.560 
0.297 
   Macrosomia (BW>4kg)b 0 0 NA 
    Large for gestational age 
   ( >90th centile)b 
0 (0)  
 
2 (8.0) 0.490 
   Small for gestational age    
   (<10th centile)b 
0 0 NA 
a Data expressed as mean±SD 
b Data expressed as n (%) 
cBW adjusted for gestation and gender calculated with the Fenton 2013 web-calculator 
(http://peditools.org/fenton2013) 
TABLE 6: Maternal and fetal outcomes in CGM and standard-care groups 
 
 
 
 
 
 
  
 
 Parametersa CGMS 1,  n=23    CGMS  3, n=23 p-value  
Time Spent in Euglycaemia(%)b 84.6±9.4 88.8±7.0 0.016 
Time spent in Hypoglycaemia (%)c 2.7±5.0 2.9±3.2 0.812 
Time spent in Hyperglycaemia (%)c 12.7±9.9 8.3±6.3 0.017 
Total Area under the curve 53230.9±19106.1 54509.0±17042.5 0.910 
Mean 24 Hour Glucose(mmol/L) 5.4±0.5 5.2±0.3 0.077 
Mean Day Time Glucose(mmol/L) 5.5±0.5 5.3±0.4 0.073 
Mean Nocturnal Glucose (mmol/L) 5.1±0.1 4.9±0.5 0.180 
AUC Above Limit(>6.7mmol/L) 0.1±0.1 0.06±0.07 0.044 
AUC Below Limit(<3.5mmol/L) 0.01±0.02 0.01±0.01 0.827 
a Data expressed as mean±SD 
b Time spent in euglycemia on CGM: glucose levels 3.5-6.7mmol/L 
c Time spent in hypoglycemia on CGM: glucose levels <3.5mmol/L  
c Time spent in hyperglycemia on CGM: glucose levels >6.7mmol/L 
 
TABLE 7: Continuous Glucose Monitoring Parameters in the intervention group 
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